<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01064570</url>
  </required_header>
  <id_info>
    <org_study_id>AIDA2000</org_study_id>
    <nct_id>NCT01064570</nct_id>
  </id_info>
  <brief_title>AIDA 2000 Guidelines</brief_title>
  <official_title>Guidelines for Treatment of Acute Promyelocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective use of RT-PCR for PML/RARa might be used to guide a total tehrapy approach in
      APL, including refined diagnosis, front-line treatment, assessment of response and
      anticipated salvage therapy for patients who undergo molecular relapse.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2000</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related toxicity event rate during the ATRA-including consolidation treatment</measure>
    <time_frame>At the end of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival, Molecular and Hematological Disease-Free and Overall Survival in each risk group</measure>
    <time_frame>At the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rates of molecular remission, after consolidation, in each risk group</measure>
    <time_frame>At the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction morbidity and mortality after the inclusion of the prophylactic measures for the ATRA Syndrome and hemorrhagic complications</measure>
    <time_frame>At the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The overall toxicity of induction, consolidation, and maintenance chemotherapy in each risk group</measure>
    <time_frame>At the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The impact on survival of a &quot;total&quot; treatment approach for APL including molecular evaluation of minimal residual disease and salvage tehrapy administration at the time of molecular or hematological relapse</measure>
    <time_frame>At the end of the study</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Acute Promyelocytic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>all-trans retinoic acid (ATRA)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 1 years and &lt; 61 years

          -  Morphologic diagnosis of APL

          -  PS &lt;= 3

          -  Presence in leukemic cells at diagnosis of t(15;17), and/or PML/RARa rearrangement by
             RT-PCR. T

          -  The presence of additional cytogenetic lesions is not considered an exclusion
             criterion

          -  Serum creatinine &lt;=2.5 mg/dL

          -  Serum bilirubin, alkaline phosphatase, or GOT/ASAT &lt;= 3 times the upper normal limit

          -  Negative pregnancy test

          -  Written informed consent

        Exclusion Criteria:

          -  Age &gt;= 61 years

          -  Prior antileukemic chemotherapy for APL

          -  Absence of PML-RARa rearrangement after successful RNA extraction and amplification of
             control gene

          -  Prior antileikemic chemotherapy for APL

          -  Presence of a concomitant malignant neoplasm, except basal cell carcinoma Concurrent
             treatment with cytotoxic chemotherapy or radiotherapy

          -  Oteher progressive malignant disease. However, secondary acute promyelocytic leukemia
             following &quot;cured&quot; Hodgkin's disease or otehr cured malignancies may be included, as
             well as secondary leukemias following other exposure to alkylating agents or radiation
             for other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Unità Operativa Ematologia 1 - Università degli Studi di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70010</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo LISO</last_name>
      <email>v.liso@ematba.uniba.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Div. di Ematologia IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario LAZZARINO</last_name>
      <email>mlazzarino@smatteo.pv.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O Umberto I</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco MANDELLI, MD, PhD</last_name>
      <email>gimema@gimema.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Breccia M, Mazzarella L, Bagnardi V, Disalvatore D, Loglisci G, Cimino G, Testi AM, Avvisati G, Petti MC, Minotti C, Latagliata R, Foà R, Pelicci PG, Lo-Coco F. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. Blood. 2012 Jan 5;119(1):49-54. doi: 10.1182/blood-2011-07-369595. Epub 2011 Nov 2.</citation>
    <PMID>22049518</PMID>
  </reference>
  <results_reference>
    <citation>Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia G, Cimino G, Diverio D, Borlenghi E, Martinelli G, Di Raimondo F, Di Bona E, Fazi P, Peta A, Bosi A, Carella AM, Fabbiano F, Pogliani EM, Petti MC, Amadori S, Mandelli F; Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010 Oct 28;116(17):3171-9. doi: 10.1182/blood-2010-03-276196. Epub 2010 Jul 19.</citation>
    <PMID>20644121</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2010</study_first_submitted>
  <study_first_submitted_qc>February 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2010</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <name_title>Prof. Franco Mandelli</name_title>
    <organization>GIMEMA</organization>
  </responsible_party>
  <keyword>Acute Promyelocytic Leukemia</keyword>
  <keyword>APL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

